

# Robert J Noveck

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2902454/publications.pdf>

Version: 2024-02-01

54  
papers

2,132  
citations

304602

22  
h-index

223716

46  
g-index

56  
all docs

56  
docs citations

56  
times ranked

2383  
citing authors

#	ARTICLE	IF	CITATIONS
1	First-in-Class Human Studies of MW0189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 131-143.	0.8	8
2	Low Plasma Gelsolin Concentrations in Chronic Granulomatous Disease. <i>Inflammation</i> , 2021, 44, 270-277.	1.7	1
3	A Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human Diseases. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 444-446.	0.8	1
4	A Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS986231 in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 717-730.	1.0	14
5	A Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human Diseases. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, , 216847901984566.	0.8	0
6	The Potential Role of the J <sub>T</sub> peak Interval in Proarrhythmic Cardiac Safety: Current State of the Science From the American College of Clinical Pharmacology and the Cardiac Safety Research Consortium. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 909-914.	1.0	13
7	Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers. <i>Clinical Immunology</i> , 2018, 191, 10-20.	1.4	25
8	Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 888-898.	2.3	3
9	The novel combination of theophylline and bambuterol as a potential treatment of hypoxemia in humans. <i>Canadian Journal of Physiology and Pharmacology</i> , 2017, 95, 1009-1018.	0.7	1
10	Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 770-776.	1.0	35
11	Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. <i>Thrombosis and Haemostasis</i> , 2017, 117, 238-245.	1.8	128
12	Proposed Strategies for the Integration of Genomics in Primary Care. <i>American Journal of Medicine</i> , 2016, 129, e87.	0.6	1
13	Safety of combined bambuterol and theophylline as a potential treatment of high altitude-induced fatigue in humans. <i>FASEB Journal</i> , 2016, 30, lb672.	0.2	0
14	Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1793-1799.	2.8	10
15	Effects of an Antisense Oligonucleotide Inhibitor of C-reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	33
16	Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban. <i>New England Journal of Medicine</i> , 2014, 371, 2141-2142.	13.9	408
17	Anti-Hypotensive Treatment and Endothelin Blockade Synergistically Antagonize Exercise Fatigue in Rats under Simulated High Altitude. <i>PLoS ONE</i> , 2014, 9, e99309.	1.1	8
18	Microdosing and drug development: past, present and future. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 817-834.	1.5	82

#	ARTICLE	IF	CITATIONS
19	Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 331-342.	1.0	179
20	A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 966-978.	1.1	38
21	Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine. <i>Drug Design, Development and Therapy</i> , 2013, 7, 619.	2.0	3
22	Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 60, 335-341.	0.8	29
23	Pharmacological Modulation of Peripheral T and B Lymphocytes by a Selective Sphingosine 1-Phosphate Receptor Modulator. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 996-1006.	1.0	12
24	Effect of Ketoconazole on the Pharmacokinetic Profile of Buprenorphine following Administration of a Once-Weekly Buprenorphine Transdermal System. <i>Clinical Drug Investigation</i> , 2012, 32, 583-592.	1.1	22
25	Effect of Ketoconazole on the Pharmacokinetic Profile of Buprenorphine following Administration of a Once-Weekly Buprenorphine Transdermal System. <i>Clinical Drug Investigation</i> , 2012, 32, 583-592.	1.1	18
26	Onset of action of diclofenac potassium liquid-filled capsules in dental surgery patients. <i>Current Medical Research and Opinion</i> , 2011, 27, 1733-1739.	0.9	18
27	Pharmacokinetic-Pharmacodynamic Modeling of Apratastat: A Population-Based Approach. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 472-481.	1.0	12
28	Controlled Phase III Clinical Trial of Diclofenac Potassium Liquid-Filled Soft Gelatin Capsule for Treatment of Postoperative Dental Pain. <i>Journal of Oral and Maxillofacial Surgery</i> , 2010, 68, 2735-2742.	0.5	17
29	Effect of the Bile Acid Sequestrant Colesevelam on the Pharmacokinetics of Pioglitazone, Repaglinide, Estrogen Estradiol, Norethindrone, Levothyroxine, and Glyburide. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 554-565.	1.0	23
30	Pharmacokinetics and Pharmacodynamics of Cinacalcet in Hepatic Impairment. <i>Clinical Drug Investigation</i> , 2008, 28, 635-643.	1.1	19
31	Pharmacokinetics of Amlodipine and Olmesartan After Administration of Amlodipine Besylate and Olmesartan Medoxomil in Separate Dosage Forms and as a Fixed-Dose Combination. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 1309-1322.	1.0	26
32	Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers. <i>Innate Immunity</i> , 2008, 14, 383-394.	1.1	20
33	Thalidomide Suppressed IL-1 <sup>2</sup> While Enhancing TNF- $\alpha$ and IL-10, When Cells in Whole Blood were Stimulated with Lipopolysaccharide. <i>Immunopharmacology and Immunotoxicology</i> , 2008, 30, 447-457.	1.1	22
34	Nasogastric Administration of Garenoxacin as Crushed Tablets With and Without Concomitant Enteral Feeding in Healthy Subjects. <i>Drugs in R and D</i> , 2007, 8, 43-50.	1.1	2
35	Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia. <i>Translational Research</i> , 2007, 150, 275-280.	2.2	27
36	Pharmacokinetics and Safety of Ebastine in Healthy Subjects and Patients with Renal Impairment. <i>Clinical Pharmacokinetics</i> , 2007, 46, 525-534.	1.6	8

#	ARTICLE	IF	CITATIONS
37	American Society for Clinical Pharmacology and Therapeutics Position Statement on Dietary Supplement Safety and Regulation*. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 113-122.	2.3	32
38	Extended in Vivo Pharmacodynamic Activity of E5564 in Normal Volunteers with Experimental Endotoxemia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 175-181.	1.3	35
39	Parecoxib Sodium, an Injectable COX-2-Specific Inhibitor, Does Not Affect Unfractionated Heparin-Regulated Blood Coagulation Parameters. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 474-480.	1.0	11
40	Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. <i>Journal of Pain and Symptom Management</i> , 2004, 28, 59-71.	0.6	142
41	Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily. <i>American Journal of Kidney Diseases</i> , 2004, 44, 1070-1076.	2.1	70
42	Pharmacokinetics and Safety of Ebastine in Patients with Impaired Hepatic Function Compared with Healthy Volunteers. <i>Clinical Pharmacokinetics</i> , 2004, 43, 121-129.	1.6	18
43	Dose-ranging analgesic study of prosorb <sup>®</sup> diclofenac potassium in postsurgical dental pain. <i>Clinical Therapeutics</i> , 2004, 26, 1215-1227.	1.1	50
44	Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. <i>American Journal of Hypertension</i> , 2003, 16, 739-745.	1.0	13
45	Blocking of Responses to Endotoxin by E5564 in Healthy Volunteers with Experimental Endotoxemia. <i>Journal of Infectious Diseases</i> , 2003, 187, 631-639.	1.9	151
46	Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 1027-30.	1.0	22
47	Parecoxib Sodium does not Impair Platelet Function in Healthy Elderly and Non-Elderly Individuals. <i>Clinical Drug Investigation</i> , 2001, 21, 465-476.	1.1	72
48	Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunction. <i>Clinical Therapeutics</i> , 2001, 23, 1180-1192.	1.1	31
49	Randomized Safety Studies of Intravenous Perflubron Emulsion. I. Effects on Coagulation Function in Healthy Volunteers. <i>Anesthesia and Analgesia</i> , 2000, 91, 804-811.	1.1	76
50	Randomized Safety Studies of Intravenous Perflubron Emulsion. II. Effects on Immune Function in Healthy Volunteers. <i>Anesthesia and Analgesia</i> , 2000, 91, 812-822.	1.1	78
51	Oxaprozin and Piroxicam, Nonsteroidal Antiinflammatory Drugs with Long Half-Lives: Effect of Protein-Binding Differences on Steady-State Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 267-278.	1.0	22
52	Extrarenal contributions to indapamide's antihypertensive mechanism of action. <i>American Heart Journal</i> , 1983, 106, 221-229.	1.2	9
53	Clonidine-chlorthalidone combination once and twice daily in essential hypertension. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 28, 581-586.	2.3	3
54	Erythropoietic Effects of 5-Hydroxytryptamine. <i>Experimental Biology and Medicine</i> , 1971, 138, 103-107.	1.1	10